Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Melanotan I (Afamelanotide) vs Melanotan II
An educational, source-based comparison of Melanotan I (Afamelanotide) and Melanotan II — how each peptide works, what it's researched for, and what to know before going deeper.
Selective MC1R agonist FDA-approved for erythropoietic protoporphyria.
A selective melanocortin-1 receptor (MC1R) agonist that stimulates eumelanin production in melanocytes. FDA-approved (Scenesse) as an implant for erythropoietic protoporphyria, a rare light-sensitive disorder.
- Erythropoietic protoporphyria (FDA-approved)
- UV-independent tanning (research)
- Photoprotection in photosensitivity disorders
- • FDA-approved for EPP via implant formulation only.
- • Not approved for cosmetic tanning.
- • Monitoring for new/changing moles recommended.
Melanocortin agonist researched for tanning response and libido.
A non-selective melanocortin receptor agonist that stimulates eumelanin production via MC1R and influences appetite, libido, and erectile function via MC3R/MC4R.
- UV-independent pigmentation
- Erythropoietic protoporphyria (related compound, afamelanotide)
- Sexual function (overlap with PT-141)
- • Not FDA-approved.
- • Risk of new or changing nevi — dermatologic monitoring is essential.
- • Common side effects: nausea, flushing, spontaneous erections, appetite suppression.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Melanotan I (Afamelanotide) | Afamelanotide for erythropoietic protoporphyria | New England Journal of Medicine | 2015 | Phase 3 trials showed significant pain reduction and sun tolerance. |
| Melanotan II | Melanotan and melanocortin receptor pharmacology | Peptides | 2005 | Reviewed pigmentation and behavioral effects of MT-II in animal and human studies. |
Side-effect & safety grid
- FDA-approved for EPP via implant formulation only.
- Not approved for cosmetic tanning.
- Monitoring for new/changing moles recommended.
- Not FDA-approved.
- Risk of new or changing nevi — dermatologic monitoring is essential.
- Common side effects: nausea, flushing, spontaneous erections, appetite suppression.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Melanotan I (Afamelanotide) vs Melanotan II — Key differences
- Class: Melanotan I (Afamelanotide) is classified as Pigmentation · Melanocortin, while Melanotan II is Pigmentation · Melanocortin.
- Primary research focus: Melanotan I (Afamelanotide) — erythropoietic protoporphyria (fda-approved); Melanotan II — uv-independent pigmentation.
- Tag: Skin · Pigmentation vs Skin · Pigmentation.